ProQR's Upcoming Presentation at 2024 Healthcare Conference
ProQR to Present at the 2024 Cantor Global Healthcare Conference
ProQR Therapeutics NV. (NASDAQ: PRQR) continues to advance its work in RNA therapies, and it’s taking that story to a major industry stage. The company announced that members of its management team will join a key healthcare gathering to discuss recent progress and where the science is headed.
Event Details and What to Expect
ProQR is scheduled to speak at the 2024 Cantor Global Healthcare Conference in New York City. The session is set for a Tuesday morning, with a fireside chat beginning at 9:10 am ET. It’s a focused window for the team to outline developments in RNA editing, share perspective on the platform, and address how their approach may translate into future treatments.
Live Webcast and Replay
If you’d like to follow along in real time, ProQR will host a live webcast. You can access it through the “Investors & Media” section on the company’s website, under “Events.” Can’t make the live slot? A recorded version will remain available for about 30 days after the session, so investors and others can catch up when it suits their schedule.
Axiomer™ RNA Editing: The Core Platform
Central to ProQR’s work is its Axiomer™ RNA editing technology. The platform is designed to open up treatment options by making precise edits at the RNA level. In practice, Axiomer™ uses short oligonucleotides to home in on a single nucleotide in RNA and direct the specific change that’s needed—an edit tailored to the error.
How Axiomer™ Works
Axiomer™ taps into a process the body already uses. It guides the enzyme ADAR (Adenosine Deaminase Acting on RNA) to convert Adenosine (A) to Inosine (I) in RNA. By steering ADAR to the right spot, the edited RNA may counteract disease-causing mutations. The aim is straightforward: restore the intended protein output or, where appropriate, enable new protein functions that could address disease. While much work remains, this approach points to a future where certain genetic disorders could be treated by repairing the message before it becomes a malfunctioning protein.
ProQR’s Focus: Turning RNA Science into Care
ProQR Therapeutics remains focused on developing RNA-based treatments that have a clear path to helping patients. The company emphasizes creative problem-solving and rigorous science to take on both rare conditions and more common diseases that still have few, if any, good options.
Building a Pipeline with Patients in Mind
The team continues to grow a pipeline rooted in its proprietary RNA repair platform. The goal is consistent: advance programs that speak to unmet medical needs, while keeping patients and families at the center of decision-making. Each candidate builds on the same underlying principle—precise RNA editing as a way to correct the message and, in turn, influence the course of disease.
Contact Information for ProQR
For additional details or investor inquiries, ProQR’s investor relations team is available. You can reach Sarah Kiely at +1 617 599 6228, or via email. Investor-related questions can also be directed to Peter Kelleher at LifeSci Advisors.
Frequently Asked Questions
When and where is ProQR presenting?
ProQR will present at the 2024 Cantor Global Healthcare Conference in New York City. The fireside chat is scheduled for Tuesday at 9:10 am ET.
How do I watch the presentation?
A live webcast will be available in the “Investors & Media” section of ProQR’s website, under “Events.” A replay will remain accessible for approximately 30 days after the live event.
What topics will ProQR cover during the session?
The team plans to discuss progress and insights related to RNA editing technologies, with a focus on the Axiomer™ platform and how it may translate to future therapies.
What is Axiomer™, in simple terms?
Axiomer™ is ProQR’s RNA editing platform. It uses oligonucleotides to guide the body’s ADAR enzyme to convert Adenosine (A) to Inosine (I) at a specific spot in RNA, a change that may help correct certain disease-causing mutations or adjust protein function.
Who can I contact with investor questions?
Please reach out to ProQR’s investor relations via Sarah Kiely at +1 617 599 6228 or by email. You can also contact Peter Kelleher at LifeSci Advisors for investor-related inquiries.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.